Drug Overview
Tracleer (bosentan; Johnson & Johnson) was the first oral therapy to be developed specifically for the treatment of PH. Tracleer is a competitive endothelin receptor type A and B antagonist, with over expression of endothelin in PH being associated with excessive vasoconstriction, pulmonary vasculature remodeling, and thrombosis formation.
Analyst Outlook
Once the market leader and the first-to-market drug for pulmonary hypertension (PH), Tracleer (bosentan; Johnson & Johnson), will now be succeeded by Johnson & Johnson’s next-generation endothelin receptor antagonist (ERA) Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku). Opsumit has demonstrated morbidity evidence that Tracleer lacks, and further possesses an improved hepatotoxicity profile. A combination of generic erosion and patients switching to Opsumit will set Tracleer’s sales into decline over the forecast period. Nevertheless, Tracleer will continue to benefit from prescribing trends increasingly integrating ERAs into combination regimens, which may help to offset losses.
Tracleer (bosentan; Johnson & Johnson) was the first oral therapy to be developed specifically for the treatment of PH. Tracleer is a competitive endothelin receptor type A and B antagonist, with over expression of endothelin in PH being associated with excessive vasoconstriction, pulmonary vasculature remodeling, and thrombosis formation.
Analyst Outlook
Once the market leader and the first-to-market drug for pulmonary hypertension (PH), Tracleer (bosentan; Johnson & Johnson), will now be succeeded by Johnson & Johnson’s next-generation endothelin receptor antagonist (ERA) Opsumit (macitentan; Johnson & Johnson/Nippon Shinyaku). Opsumit has demonstrated morbidity evidence that Tracleer lacks, and further possesses an improved hepatotoxicity profile. A combination of generic erosion and patients switching to Opsumit will set Tracleer’s sales into decline over the forecast period. Nevertheless, Tracleer will continue to benefit from prescribing trends increasingly integrating ERAs into combination regimens, which may help to offset losses.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES